Condition: Cisplatin-induced Ototoxicity · Sensorineural Hearing Loss · Ototoxicity · Sponsor: Siriraj Hospital
The purpose of this study is to evaluate the efficacy of N-acetylcysteine (NAC) in preventing cisplatin-induced ototoxicity in patients receiving cisplatin-based chemotherapy. Cisplatin is a highly effective chemotherapeutic agent but often leads to permanent hearing loss (ototoxicity) as a significant side effect. This study investigates whether the administration of NAC as an otoprotective agent can reduce or prevent the decline in hearing sensitivity, particularly at extended high frequencies, as measured by audiometry and distortion product otoacoustic emissions (DPOAE).
This description comes directly from the study's public registry record.
Naphassakorn Opasatian, Bachelor · 66982469575 · maymnoshikal@gmail.com
Always discuss trial participation with your own doctor first.
| Faculty of Medicine Siriraj Hospital, Mahidol University | Bangkok, Bangkoknoi, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07364747